Sea Lane Biotechnologies, Menlo Park, California, United States of America.
PLoS Pathog. 2010 Jul 8;6(7):e1000990. doi: 10.1371/journal.ppat.1000990.
Influenza viruses elude immune responses and antiviral chemotherapeutics through genetic drift and reassortment. As a result, the development of new strategies that attack a highly conserved viral function to prevent and/or treat influenza infection is being pursued. Such novel broadly acting antiviral therapies would be less susceptible to virus escape and provide a long lasting solution to the evolving virus challenge. Here we report the in vitro and in vivo activity of a human monoclonal antibody (A06) against two isolates of the 2009 H1N1 pandemic influenza virus. This antibody, which was obtained from a combinatorial library derived from a survivor of highly pathogenic H5N1 infection, neutralizes H5N1, seasonal H1N1 and 2009 "Swine" H1N1 pandemic influenza in vitro with similar potency and is capable of preventing and treating 2009 H1N1 influenza infection in murine models of disease. These results demonstrate broad activity of the A06 antibody and its utility as an anti-influenza treatment option, even against newly evolved influenza strains to which there is limited immunity in the general population.
流感病毒通过遗传漂移和重配来逃避免疫反应和抗病毒化学疗法。因此，人们正在寻求开发新的策略，攻击高度保守的病毒功能，以预防和/或治疗流感感染。这种新型的广泛作用的抗病毒疗法不太容易受到病毒逃逸的影响，并为不断演变的病毒挑战提供持久的解决方案。在这里，我们报告了一种针对 2009 年 H1N1 大流行流感病毒的两种分离株的人源单克隆抗体（A06）的体外和体内活性。该抗体是从高致病性 H5N1 感染幸存者的组合文库中获得的，能够中和 H5N1、季节性 H1N1 和 2009 年“猪”H1N1 大流行流感，体外效力相似，并且能够预防和治疗疾病的小鼠模型中的 2009 年 H1N1 流感感染。这些结果表明 A06 抗体具有广泛的活性，可用作抗流感治疗选择，甚至可用于针对普通人群中免疫有限的新出现的流感株。
